Brief Communication: Attitudes and Preferences of Long-acting Injectable HIV Preexposure Prophylaxis Among Thai Adolescents and Young Adults

Overview

Journal AIDS Res Ther

Publisher Biomed Central

Specialty Infectious Diseases

Date 2025 Mar 2

PMID 40025583

Authors

Alisa Wongsethanatada

Wipaporn Natalie Songtaweesin

Prissana Wongharn

Juthamanee Moonwong

Sasiprapha Khamthi

Lucksanapon Pitikawinwong

Thanyawee Puthanakit

Affiliations

Soon will be listed here.

Abstract

This study aimed to explore willingness to use and preference for long-acting injectable PrEP (LAI-PrEP) among Thai youth at risk of HIV. A cross-sectional study was conducted in 100 Thai youth aged 18 to 24 years attending a sexual health clinic in Bangkok, Thailand. Participants received information about oral and LAI-PrEP before completing a questionnaire. Of the 98 participants willing to use pre-exposure prophylaxis, 47 preferred the injectable form. Preference for the injectable form was higher among individuals not currently using oral pre-exposure prophylaxis, affordability and longer injection intervals were key for acceptance of long-acting injectable pre-exposure prophylaxis.

References

Camfield C, Evans Y, Kumbhakar R . HIV preexposure prophylaxis in adolescents and young adults: an update. Curr Opin Pediatr. 2024; 36(4):389-399. DOI: 10.1097/MOP.0000000000001357. View

Durosinmi-Etti O, Nwala E, Oki F, Ikpeazu A, Godwin E, Umoh P . Willingness to Pay for HIV Prevention Commodities Among Key Population Groups in Nigeria. Glob Health Sci Pract. 2022; 10(5). PMC: 9622283. DOI: 10.9745/GHSP-D-21-00303. View

Ogunbajo A, Tsai A, Kanki P, Mayer K . Acceptability of and Preferences for Long-Acting Injectable HIV PrEP and Other PrEP Modalities among Sexual Minority Men in Nigeria, Africa. AIDS Behav. 2022; 26(7):2363-2375. PMC: 10921337. DOI: 10.1007/s10461-022-03575-y. View

Fu J, Dai Z, Wang H, Si M, Chen X, Wu Y . Willingness to use long-acting injectable PrEP among HIV-negative/unknown men who have sex with men in mainland China: A cross-sectional online survey. PLoS One. 2023; 18(10):e0293297. PMC: 10586652. DOI: 10.1371/journal.pone.0293297. View

Pebody R . Injectable PrEP comes to southern Africa. Lancet HIV. 2024; 11(11):e724-e725. DOI: 10.1016/S2352-3018(24)00274-1. View

Kamya M, Balzer L, Ayieko J, Kabami J, Kakande E, Chamie G . Dynamic choice HIV prevention with cabotegravir long-acting injectable in rural Uganda and Kenya: a randomised trial extension. Lancet HIV. 2024; 11(11):e736-e745. PMC: 11753513. DOI: 10.1016/S2352-3018(24)00235-2. View

Bekker L, Das M, Abdool Karim Q, Ahmed K, Batting J, Brumskine W . Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women. N Engl J Med. 2024; 391(13):1179-1192. DOI: 10.1056/NEJMoa2407001. View

Weld E, Rana M, Dallas R, Camacho-Gonzalez A, Ryscavage P, Gaur A . Interest of Youth Living With HIV in Long-Acting Antiretrovirals. J Acquir Immune Defic Syndr. 2018; 80(2):190-197. PMC: 6331217. DOI: 10.1097/QAI.0000000000001896. View

Oldenburg C, Le B, Huyen H, Thien D, Quan N, Biello K . Antiretroviral pre-exposure prophylaxis preferences among men who have sex with men in Vietnam: results from a nationwide cross-sectional survey. Sex Health. 2016; . PMC: 5253341. DOI: 10.1071/SH15144. View

10.

Landovitz R, Hanscom B, Clement M, Tran H, Kallas E, Magnus M . Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a.... Lancet HIV. 2023; 10(12):e767-e778. PMC: 11375758. DOI: 10.1016/S2352-3018(23)00261-8. View

11.

Rungmaitree S, Werarak P, Pumpradit W, Phongsamart W, Lapphra K, Wittawatmongkol O . A pilot program of HIV pre-exposure prophylaxis in Thai youth. PLoS One. 2024; 19(2):e0298914. PMC: 10883585. DOI: 10.1371/journal.pone.0298914. View

12.

Paudel K, Gupta S, Gautam K, Wickersham J, Khati A, Azwa I . High Interest in Long-acting Injectable Pre-exposure Prophylaxis (LAI-PrEP) for HIV Prevention Among Men Who Have Sex With Men (MSM): Result From A Nationwide Survey in Malaysia. J Community Health. 2023; 48(3):513-521. PMC: 10200758. DOI: 10.1007/s10900-023-01195-8. View

13.

Schoenberg P, Edwards O, Merrill L, Acero Martinez C, Stephenson R, Sullivan P . Willingness to use and preferences for long-acting injectable PrEP among sexual and gender minority populations in the southern United States, 2021-2022: cross-sectional study. J Int AIDS Soc. 2023; 26(3):e26077. PMC: 10034617. DOI: 10.1002/jia2.26077. View

14.

Cole S, Glick J, Campoamor N, Sanchez T, Sarkar S, Vannappagari V . Willingness and preferences for long-acting injectable PrEP among US men who have sex with men: a discrete choice experiment. BMJ Open. 2024; 14(4):e083837. PMC: 11043728. DOI: 10.1136/bmjopen-2023-083837. View

15.

Delany-Moretlwe S, Hughes J, Bock P, Ouma S, Hunidzarira P, Kalonji D . Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022; 399(10337):1779-1789. PMC: 9077443. DOI: 10.1016/S0140-6736(22)00538-4. View

16.

Landovitz R, Tao L, Yang J, de Boer M, Carter C, Das M . Type 1 Human Immunodeficiency Virus (HIV-1) Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-exposure Prophylaxis: Pooled Analysis From 72 Global Studies. Clin Infect Dis. 2024; 79(5):1197-1207. PMC: 7616831. DOI: 10.1093/cid/ciae143. View

17.

Songtaweesin W, Kawichai S, Phanuphak N, Cressey T, Wongharn P, Saisaengjan C . Youth-friendly services and a mobile phone application to promote adherence to pre-exposure prophylaxis among adolescent men who have sex with men and transgender women at-risk for HIV in Thailand: a randomized control trial. J Int AIDS Soc. 2020; 23 Suppl 5:e25564. PMC: 7459171. DOI: 10.1002/jia2.25564. View